5-Minute Journal Club — ASCO 2010 Presentations

Submitted by web@researchtop... on Tue, 07/06/2010 - 11:15

5-Minute Journal Club — ASCO 2010 Presentations

Read All Issues

CME Test

CE Information and Faculty Disclosures

OVERVIEW OF ACTIVITY

Each year, thousands of clinicians and basic scientists sojourn to the American Society of Clinical Oncology (ASCO) Annual Meeting to learn about recent clinical advances that yield alterations in state-of-the-art management for all tumor types. Attracting tens of thousands of attendees from every corner of the globe to both unveil and digest the latest research, ASCO is unmatched in attendance and clinical relevance. Results presented from ongoing trials lead to the emergence of new therapeutic agents and changes in the indications for existing treatments across all cancer medicine. Despite the importance of the conference, the demands of routine practice often limit the amount of time oncology clinicians can realistically dedicate to travel and learning. To bridge the gap between research and patient care, this CME activity will deliver a serial review of the key presentations from the ASCO Annual Meeting and expert perspectives on how these new evidence-based concepts can be applied to routine clinical care. This activity will assist medical oncologists and other cancer clinicians in the formulation of optimal clinical management strategies for patients with diverse forms of cancer.

LEARNING OBJECTIVES

Please see individual web programs for CME program-specific information.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Please see individual web programs for CME program-specific information.

HOW TO USE THIS CME ACTIVITY

Please see individual web programs for CME program-specific information.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Please see individual web programs for CME program-specific information.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, Lilly USA LLC, Millennium Pharmaceuticals Inc, Monogram BioSciences Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This program is supported by educational grants from Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology and Millennium Pharmaceuticals Inc.

Hardware/Software Requirements:

An Internet connection that is at least 28.8 Kbps

A monitor set to 1280 x 1024 pixels or more

Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer

Macromedia Flash plug-in 6.0 or greater

Adobe Acrobat Reader

(Optional) Sound card and speakers for audio

Last review date: June/July 2010
Expiration date: June/July 2011

Overview

This eight-part web program is part of an email series designed for dedicated but frenzied oncology professionals attempting to keep up with an exploding clinical research database. Subscribers to this program receive twice-weekly emails that include links to slides from important data sets presented at ASCO 2010 along with brief comments from clinical investigators about the significance of these results.

Current Issue

The Beginning of the End of Melanoma?
Read Dr Love’s original email (from July 6, 2010)

Or go directly to our slides and commentary on:
Ipilimumab or the gp100 Vaccine or the Combination of Both as Therapy for Patients with Metastatic Melanoma

Program Description: A summary of the results of a Phase III randomized study evaluating ipilimumab, the peptide vaccine gp100 or the combination of both for patients with previously treated metastatic melanoma.

Full Abstracts: O’Day S et al. A Phase III randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. Proc ASCO 2010;Abstract 4.

Hodi FS et al. Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma. Proc ASCO 2010;Abstract 8509.

Hodi FS et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;[Epub ahead of print]. Abstract

Ipilimumab Monotherapy for Patients with Melanoma and Brain Metastases

Program Description: A summary of the results of a Phase II study evaluating ipilimumab monotherapy for patients with melanoma and brain metastases.

Full Abstract: Lawrence DP et al. Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases. Proc ASCO 2010;Abstract 8523.

B-raf Kinase Inhibitor GSK2118436 as Therapy for Patients with Metastatic Melanoma and Other Solid Tumors

Program Description: A summary of the results of a Phase I/II study evaluating the maximum tolerated dose and safety of the B-raf kinase inhibitor GSK2118436 for patients with metastatic melanoma and other solid tumors.

Full Abstract: Kefford R et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. Proc ASCO 2010;Abstract 8503.

Previous Issues

Biologic Treatment of Ovarian Cancer
Read Dr Love's original email (from June 30, 2010)

Or go directly to our slides and commentary on:
Bevacizumab in the Primary Treatment of Advanced Ovarian, Peritoneal or Fallopian Tube Carcinoma

Program Description: A summary of results of the GOG-0218 Phase III study investigating the up-front use of bevacizumab in the treatment of advanced ovarian, peritoneal or fallopian tube carcinoma.

Full Abstract: Burger RA et al. Phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal or fallopian tube cancer: A Gynecologic Oncology Group (GOG) study. Proc ASCO 2010;Abstract LBA1.

Correlation of BRCA Mutation Status with Responses to Platinum Therapy and PARP Inhibitors in Patients with Ovarian Cancer and Triple-Negative Breast Cancer (TNBC)

Program Description: A summary of the results of studies investigating tumor response using serial tumor biopsies to determine markers of response in advanced serous ovarian cancer and TNBC and the correlation of distinct gene expression profiles (BRCA-like and non-BRCA-like) with clinical outcome and responsiveness to platinum therapy and PARP inhibitors in sporadic ovarian tumors.

Full Abstracts: Gelmon KA et al. Can we define tumors that will respond to PARP inhibitors? A Phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. Proc ASCO 2010;Abstract 3002.

Konstantinopoulos PA et al. A gene expression profile of BRCAness that correlates with responsiveness to platinum, PARP inhibitors and with outcome in epithelial ovarian cancer. Proc ASCO 2010;Abstract 5004.

Konstantinopoulos PA et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010;[Epub ahead of print]. Abstract

AMG 386, an Angiogenesis Inhibitor, in the Treatment of Recurrent Ovarian, Peritoneal or Fallopian Tube Carcinoma

Program Description: A summary of results of a Phase II study investigating the combination of anti-angiogenic agent AMG 386 and paclitaxel in the treatment of recurrent ovarian, peritoneal or fallopian tube carcinoma.

Full Abstract: Karlan BY et al. Randomized, double-blind, placebo-controlled, Phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. Proc ASCO 2010;Abstract 5000.